Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP: 1.Navigating Second-Line Treatments and CAR T-Cell Therapy for DLBCL: Insights from Dr. Budde and Dr. Lunning

Now Viewing

EP: 2.Dr Locke, Dr Hunter, Dr Lunning Share Referral Patterns in Their Practices

EP: 3.Dr Locke Shares Key Takeaways from ZUMA-7 and TRANSFORM Studies

EP: 4.Dr Gordon Shares Key Takeaways from ALYCANTE and PILOT for 2L CAR T-cell Transplant-Ineligible Population

EP: 5.Dr Hunter Shares Key Takeaways from L-MIND 5-Year Data and RE-MIND2 Study

EP: 6.Panel Discuses Use of CD19 Bispecifics in Sequencing

EP: 7.Panel Discusses Challenges with CAR T Therapy in R/R DLBCL, Particularly Around T-cell Exhaustion

EP: 8.Current Approach to Bridging Therapy in R/R DLBCL

EP: 9.Risk of Secondary Malignancies in Heavily Pre-Treated Population

EP: 10.Management of CRS and ICANS with CAR T-cell Therapy

EP: 11.Third-line Treatment Options for DLBCL After CAR T-cell Therapy or ASCT in Second-line

EP: 12.Contemporary Sequencing CD20xCD3 Bispecific Antibody R/R DLBCL Who Have progressed beyond CAR T-cell therapy

EP: 13.Bispecific therapy – treatment setting and management of short-term adverse events

EP: 14.Bispecific therapy – management of long-term adverse events in the community setting

EP: 15.Practice Patterns and Real Use of Epcoritamab and Glofitamab

EP: 16.Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL

Video content above is prompted by the following:

• What clinical factors do you consider for patients with R/R DLBCL who are primary refractory or experience early relapse in determining transplant eligibility?
  • When CAR T-cell therapy is the best option for your patient, how does the manufacturing process time line affect your decisions?
    • Are most community oncologists referring to CAR T-cell centers or keeping their patients?
    • How early are patients being referred to your center (eg, second-line, third-line)?
    • When do you initiate the collection/production process?
    • What is the primary impetus for early referral?